Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $5.54

Posted by Stanley Muller on Jun 28th, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.54.

A number of brokerages have recently issued reports on ESPR. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. HC Wainwright lowered shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price for the company. in a research note on Friday, May 1st. Jefferies Financial Group lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Cantor Fitzgerald lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st.

Check Out Our Latest Stock Analysis on Esperion Therapeutics

Esperion Therapeutics Trading Up 0.6%

ESPR opened at $3.17 on Friday. Esperion Therapeutics has a 12-month low of $0.95 and a 12-month high of $4.18. The business’s fifty day simple moving average is $2.88 and its 200-day simple moving average is $3.09. The company has a market capitalization of $816.88 million, a price-to-earnings ratio of -52.83 and a beta of 1.07.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The business had revenue of $80.10 million during the quarter, compared to analysts’ expectations of $84.52 million.

Insider Activity

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 10,773 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total transaction of $33,934.95. Following the sale, the chief financial officer owned 702,829 shares in the company, valued at $2,213,911.35. This represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin Looker sold 11,824 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total value of $37,245.60. Following the sale, the insider owned 667,524 shares in the company, valued at approximately $2,102,700.60. This trade represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Sivia Capital Partners LLC acquired a new position in shares of Esperion Therapeutics during the 2nd quarter worth about $25,000. R Squared Ltd acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $33,000. Kestra Advisory Services LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $35,000. KFG Wealth Management LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $37,000. Finally, Cary Street Partners Financial LLC acquired a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $38,000. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.